Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)

NCT04748263•Centre Hospitalier Princesse Grace

Summary

It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind), are associated with social behavior disorders. This kind of disorders are observed in Fronto-Temporal Dementia (FTD), Alzheimer's Dementia (AD) and Parkinson's Disease (PD), with severe deficits in FTD and lighter deficits in AD and PD. One explanation might be that patients apply inappropriate visual exploration strategies to decode emotions and intentions of others. This study aims to test this hypothesis and further to analyse whether different patterns emerge from these pathologies.

Eligibility

Age

45 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hospitalized or coming to perform a consultation, for whom an Eye-Tracking examination is indicated as part of routine care.
•Sufficient written and oral expression in French.
•Written informed consent signed by the patient.
•For the control group: No cognitive impairment (non pathological MMSE (according to age, gender and socio-cultural level), no neurological history, and no psychiatric history (especially anxiety and depressive disorders).
•For the FTD group: Patient diagnosed according to revised Rascovsky et al. 2011., no neurological history (excepted diagnosed FTD), and no psychiatric history (excepted those related to diagnosed FTD).
•For the AD group: Patient diagnosed according to DSM-IV-TR criteria, no neurological history (excepted diagnosed AD), and no psychiatric history (excepted those related to diagnosed AD).
•For the PD group: Patient diagnosed according to NINDS criteria, no neurological history (excepted diagnosed PD), and no psychiatric history (excepted those related to diagnosed PD).

Exclusion Criteria

•General anaesthesia within 3 months.
•Ophthalmological problems preventing a video-oculography examination.
•Oculomotor disorders such as "fixation disorders" or "ocular tracking disorders".
•Cognitive disorders of the type: visual agnosia, visuo-spatial disorder, visuo-perceptual disorder or aphasia.
•History of stroke.
•History of alcohol or drug abuse.

Key Dates

Start Date

July 1, 2015

Primary Completion Date

December 1, 2019

Completion Date

November 1, 2020

Last Updated

February 10, 2021

Enrollment

ACTUAL participants

Conditions

Alzheimer's DementiaParkinson Disease(PD)Fronto-Temporal Dementia

Interventions

No intervention. Only survey and normal use of eye-tracking

OTHER

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy

NCT06875739

Neurodegenerative DisordersParkinson Disease+4 more

View study

NOT_YET_RECRUITINGPHASE1

hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

NCT06607900

Alzheimer DiseaseParkinson Disease+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)

Inclusion Criteria

Exclusion Criteria

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy

hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia

Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia